Please ensure Javascript is enabled for purposes of website accessibility

Why Vertex Pharmaceuticals Stock Is Slumping Today

By George Budwell – Oct 15, 2020 at 8:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are concerned about Vertex's pipeline after a rare miss in the clinic.

What happened

Shares of rare-disease specialist Vertex Pharmaceuticals (VRTX -1.11%) fell by as much as 15.7% in pre-market trading Thursday morning. The biotech's stock is under pressure today due to a worrying safety signal observed in a midstage trial for the small-molecule drug VX-814 as a potential treatment for alpha-1 antitrypsin deficiency (AATD). 

Specifically, the drug's development is reportedly being discontinued after several patients in the study exhibited elevated liver enzymes. AATD is a genetically based condition associated with an increased risk of lung and liver disease.

Falling stock chart superimposed over columns of blue numbers

Image source: Getty Images.

So what

If this double-digit drop in pre-market trading holds, Vertex will lose approximately $10 billion in market capitalization today. While VX-814 stood to be a decent revenue generator for the company, the truth is that this drug would have likely faced stiff competition as an AATD treatment.

Biotechs like Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Dicerna Pharmaceuticals are developing rival AATD therapies, after all. Vertex's sharp pullback today, in turn, seems to be more about shareholders' concerns about the company's non-cystic fibrosis assets -- a market where it sports a virtual monopoly -- than it is about this rare clinical setback.    

Now what

Vertex isn't throwing in the towel on AATD, however. The biotech announced in the same press release that its other midstage candidate, VX-864, remains on track to produce top-line data sometime in the first half of 2021. What's important to understand is that VX-864 is structurally distinct from VX-814 -- meaning that this clinical failure shouldn't be taken as a preview of things to come for VX-864.

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$289.54 (-1.11%) $-3.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.